ABBV
AbbVie Inc
AbbVie Inc historical holders
total: 14
Gardner Russo & Quinn AbbVie Inc transactions over time
- Total transactions:
- 21
- New positions:
- 1
- Added:
- 5
- Reduced:
- 15
- Held since:
- 2013 Q2 or earlier
- Held for:
- 52+ quarters
- Latest activity:
- 2024 Q4
Thomas Russo has been an institutional investor in AbbVie Inc (ABBV) since at least 2013 Q2. According to 2026 Q1 report, Thomas Russo holds 12,410 shares with a market value of roughly $2.70M representing 0.03% of their equity portfolio. In our earliest available record from 2013 Q2, Gardner Russo & Quinn held 87,127 shares of ABBV. Since at least 2013 Q2, Gardner Russo & Quinn has made 20 more transactions in this position.
Does Thomas Russo still hold ABBV?
Yes, Thomas Russo continues to hold AbbVie Inc (ABBV). According to their 2026 Q1 report, they maintain a position of 12,410 shares valued at approximately $2.70M, representing 0.03% of their equity portfolio.
Estimated cost basis*
- Weighted AVG buy price:
- $42.63
- Weighted AVG sell price:
- $60.67
ABBV transactions history by Gardner Russo & Quinn
21 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q4
|
0.02%
|
12,410
|
$177.70
|
$2,205,257
|
-0.80% (-100)
|
-0%
|
|
2023 Q4
|
0.02%
|
12,510
|
$154.97
|
$1,938,675
|
-0.58% (-73)
|
-0%
|
|
2023 Q3
|
0.02%
|
12,583
|
$149.06
|
$1,875,622
|
-0.06% (-8)
|
-0%
|
|
2023 Q2
|
0.02%
|
12,591
|
$134.73
|
$1,696,385
|
-0.15% (-19)
|
-0%
|
|
2022 Q2
|
0.02%
|
12,610
|
$153.13
|
$1,931,000
|
-2.32% (-300)
|
-0%
|
|
2021 Q3
|
0.01%
|
12,910
|
$107.90
|
$1,393,000
|
+2.38% (+300)
|
+0%
|
|
2020 Q3
|
0.01%
|
$87.63
|
+0.13% (+16)
|
|||
|
2020 Q2
|
0.01%
|
$98.14
|
+0.67% (+84)
|
|||
|
2020 Q1
|
0.01%
|
$76.18
|
-2.34% (-300)
|
|||
|
2019 Q4
|
0.01%
|
$88.52
|
-1.54% (-200)
|
|||
|
2019 Q1
|
0.01%
|
$80.55
|
-6.85% (-956)
|
|||
|
2018 Q2
|
0.01%
|
$92.65
|
+1.94% (+266)
|
|||
|
2018 Q1
|
0.01%
|
$94.67
|
-2.84% (-400)
|
|||
|
2017 Q4
|
0.01%
|
$96.74
|
-20.79% (-3,700)
|
|||
|
2017 Q3
|
0.01%
|
$88.88
|
+9.88% (+1,600)
|
|||
|
2017 Q1
|
0.01%
|
$65.19
|
-5.30% (-906)
|
|||
|
2016 Q2
|
0.01%
|
$61.91
|
-21.24% (-4,612)
|
|||
|
2016 Q1
|
0.01%
|
$57.14
|
-74.96% (-65,000)
|
|||
|
2014 Q4
|
0.05%
|
$65.44
|
-0.07% (-59)
|
|||
|
2013 Q3
|
0.04%
|
$44.74
|
-0.40% (-350)
|
|||
|
2013 Q2
|
0.04%
|
$41.34
|
new or own*
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.